Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 277 institutions reported holding it in 13F filings for Q2 2026, worth $3.75B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
13F holders, Q4 2023
Institutional positions in Beam Therapeutics Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 185
- −7 vs. Q3 2023
- Shares held
- 68.9M
- +1.54M (+2.3%) vs. Q3 2023
- Total value
- $1.88B
- +$255.4M (+15.8%) vs. Q3 2023
- New holders
- 32
- 64 more added
- Sold out
- 39
- 56 more reduced
3 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BEAM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 277 | $3.75B |
| Q1 2026 | 253 | $2.58B |
| Q4 2025 | 247 | $2.96B |
| Q3 2025 | 219 | $2.59B |
| Q2 2025 | 218 | $1.84B |
| Q1 2025 | 238 | $1.99B |
| Q4 2024 | 232 | $2.02B |
| Q3 2024 | 221 | $1.94B |
| Q2 2024 | 214 | $1.82B |
| Q1 2024 | 221 | $2.32B |
| Q4 2023 | 185 | $1.88B |
| Q3 2023 | 195 | $1.62B |
| Q2 2023 | 194 | $2.05B |
| Q1 2023 | 207 | $1.85B |
| Q4 2022 | 209 | $2.18B |
| Q3 2022 | 225 | $2.60B |
| Q2 2022 | 206 | $2.09B |
| Q1 2022 | 240 | $2.82B |
| Q4 2021 | 232 | $3.63B |
| Q3 2021 | 232 | $3.93B |
| Q2 2021 | 231 | $5.85B |
| Q1 2021 | 210 | $3.44B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Beam Therapeutics Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −11,785−100.0% | Sold out |
| Artal Group S.A. | 0 | $0 | 0.00% | −10,975−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −10,548−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −9,899−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −9,812−100.0% | Sold out |
| Seven Eight Capital, LP | 0 | $0 | 0.00% | −9,747−100.0% | Sold out |
| JustInvest LLC | 0 | $0 | 0.00% | −8,993−100.0% | Sold out |
| Stonehage Fleming Financial Services Holdings Ltd | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| WR Wealth Planners, LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Rational Advisors LLC | 0 | $0 | 0.00% | −126−100.0% | Sold out |
| Headinvest, LLC | 0 | $0 | 0.00% | −160−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −92−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −53−100.0% | Sold out |
| Grove Bank & Trust | 0 | $0 | 0.00% | −53−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Baker Avenue Asset Management, LP | 0 | $0 | 0.00% | −29−100.0% | Sold out |
| Authentikos Wealth Advisory, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Impact Partnership Wealth, LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Tfo-TDC, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Legacy Financial Group LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Avion Wealth | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| International Biotechnology Trust PLC | – | – | – | – | Not filed |
| Virginia Retirement Systems Et Al | – | – | – | – | Not filed |
| Jacob Asset Management of New York LLC | – | – | – | – | Not filed |